Page 76 - GlaxoSmithKline Pharmaceuticals AR 2012

72
Rupees
in lakhs
Previous year
Rupees
in lakhs
a. CASH FLOW FROM OPERATING ACTIVITIES
Profit before taxation and exceptional items .. .. .. .. 982,57.82 927,33.18
Adjustments for :
Provision written back as no longer required .. .. .. .. (3,02.52) (14,60.97)
Profit on sale / disposal of fixed assets (net) .. .. .. .. (18.30) (87.84)
Profit on sale / redemption of investments .. .. .. .. — (11.90)
Interest income .. .. .. .. .. .. .. (174,64.36) (145,49.01)
Interest expense .. .. .. .. .. .. .. 33.42 32.74
Provision / write off for doubtful debts, loans and advances (net) .. 4,62.25 1,09.27
Depreciation .. .. .. .. .. .. .. 17,83.93 20,40.78
Unrealised foreign currency gains .. .. .. .. .. 4.35 (11.28)
Operating profit before working capital changes .. .. .. .. 827,56.59 787,94.97
Adjustments for :
Inventories .. .. .. .. .. .. .. 47,33.18 (50,72.96)
Trade Receivables .. .. .. .. .. .. (32,53.75) (39,37.78)
Short-term loans and advances .. .. .. .. .. (8,72.75) 7,27.89
Other current assets .. .. .. .. .. .. 53.25 40.53
Other non-current assets .. .. .. .. .. .. 19,59.32 (71.60)
Long-term loans and advances .. .. .. .. .. (12,03.83) (4,83.72)
Trade payables .. .. .. .. .. .. 34,13.35 10,12.33
Provisions .. .. .. .. .. .. .. (2,33.26) 13,70.02
Other current liabilities .. .. .. .. .. .. 5,80.85 (8,34.82)
Other long-term liabilities .. .. .. .. .. .. (3.14) (59.31)
Cash generated from operations.. .. .. .. .. .. 879,29.81 714,85.55
Direct taxes paid (net of refunds) (including fringe benefits tax) .. .. (318,37.86) (316,53.43)
Cash flow before exceptional items .. .. .. .. .. 560,91.95 398,32.12
Exceptional items:
Payments under Voluntary Retirement Scheme .. .. .. .. (91,12.19) (9,12.62)
Payment of deposits for pricing matters .. .. .. .. .. (136,82.00) (53,10.77)
Non recurring expenses for merger / rationalisation initiatives .. .. .. (19,38.50) (72.21)
Net cash from operating activities .. .. .. .. .. A 313,59.26 335,36.52
b. CASH FLOW FROM INVESTING ACTIVITIES
Purchase of tangible fixed assets .. .. .. .. .. (39,07.63) (42,53.70)
Sale of tangible fixed assets .. .. .. .. .. .. 33.51 2,45.60
Sale / redemption of current investments .. .. .. .. .. 57,00.00 5,28.00
Investment in bank deposits (having original maturity more than 3 months) .. (2219,75.00) (1694,00.00)
Redemption / Maturity of bank deposits (having original maturity more than
3 months) .. .. .. .. .. .. .. 1930,60.00 1953,25.00
Interest received .. .. .. .. .. .. .. 161,24.11 133,58.04
Net cash (used) / from investing activities .. .. .. .. B (109,65.01) 358,02.94
GlaxoSmithKline Pharmaceuticals Limited
Consolidated Cash Flow Statement for the year ended
31st December, 2012